ADVERTISEMENT

Pricing Debate

France: Government Collapses As Controversial Price-Cutting Finance Bill Rejected

The collapse of the French government brings more uncertainty for the pharmaceutical industry.

HTA Bodies In England, US and Canada Collaborate On Developing Health Economic Methods

A new, international group of health technology assessment agencies will work together on topics related to health economic methods that could include dynamic pricing and non-traditional ways of evaluating value in cost-effectiveness analyses.

Apotex And Heritage Reach $50m Settlements For US Price-Fixing Claims

Two more generics manufacturers have settled claims with 50 US attorneys general that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.

Apotex And Heritage Reach $50m Settlements For US Price-Fixing Claims

Two more generics manufacturers have reached agreements with 50 US attorneys general settling claims that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to cause a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the companies that have been part of pricing discussions.

New German Research Law Fails To Stop Companies From Opting Out Of The Market

Germany’s Medical Research Act has cleared its final legal hurdle after the federal council signed it off.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

French Bill Calls For €1bn In Drug Price Cuts, Simplifies Payback Mechanism

The 2025 social security financing bill includes measures to reduce spending on reimbursed drug costs, change the way that industry paybacks are calculated, and tackle medicine shortages.

For Generic Manufactures, New Medicare Drug Pricing Demo Is a Dud

The proposed CMS innovation center's $2 drug list model will not address the barriers to newer generics getting on Part D formularies and plans may have little incentive to participate in the demo, an industry group said.

Pink Sheet Podcast: Inside Medicare Price Negotiations, New US FDA Vaccine Pathway

Pink Sheet reporter and editors discuss experts’ experience helping drug sponsors negotiate prices with CMS and the FDA’s proposal for a new pathway to update vaccines before a pandemic is declared.